慢性肾脏病合并骨质疏松症治疗的研究进展

doi:10.3969/j.issn.1004-583X.2023.12.016

摘要/Abstract

摘要：

老年人通常并存慢性肾脏病(CKD)和骨质疏松症,CKD导致的生化异常及与年龄相关的骨质流失等危险因素对骨折的风险有累积效应。因此,骨质疏松症的治疗是当前重要的临床问题。近年来,新药的研发为治疗CKD合并骨质疏松症提供了新的可能性。本文旨在回顾目前关于CKD合并骨质疏松症的机制和治疗药物开发的临床研究做一综述,以期为临床用药提供参考。

关键词: 慢性肾脏病-矿物质和骨代谢异常, 骨质疏松症, 药物疗法, 生物因子, 地舒单抗

中图分类号:

R681.1

刘亚鑫, 郭岚, 王泽凯, 牛凯. 慢性肾脏病合并骨质疏松症治疗的研究进展[J]. 临床荟萃, 2023, 38(12): 1146-1149.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.12.016

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I12/1146

参考文献 34

[1]	Erratum: kidney disease: improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int suppl. 2017;7:1-59[J]. Kidney Int Suppl, 2017, 7(3): e1.
[2]	Diana VP. mSphere of influence: It's not me, it's you-how donor factors influence kidney transplant outcomes[J]. mSphere, 2020, 5(1):e00964-e009619.
[3]	Mahmoud MS, Mohamed A, Sherouk E, et al. Secondary osteoporosis and metabolic bone diseases[J]. J Clin Med, 2022, 11(9):2382. doi: 10.3390/jcm11092382 URL
[4]	Nishat T, Priyata D, Jannatun N, et al. Osteoporosis, an inevitable circumstance of chronic kidney disease: A systematic review[J]. Cureus, 2021, 13(10): e18488.
[5]	Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: A systemic review[J]. Int J Mol Sci, 2020, 21(18):6846. doi: 10.3390/ijms21186846 URL
[6]	Liu C, Li H. Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin d deficiency[J]. Expe Ther Med, 2019, 17(1): 368-372.
[7]	Yoshiko I, Junichiro JK, Masafumi Fukagawa. Molecular abnormalities underlying bone fragility in chronic kidney disease[J]. BioMed Resear Int, 2017, 2017: 3485785.
[8]	Hou YC, Lu CL, Lu KC, et al. Mineral bone disorders in chronic kidney disease[J]. Nephrology (Carlton), 2018, 23(Suppl 4): 88-94. doi: 10.1111/nep.2018.23.issue-S4 URL
[9]	Hanne SJ, Karel D, Syazrah S, et al. Traditional and non-traditional risk factors for osteoporosis in CKD[J]. Calcif Tissue Int, 2021, 108(4): 496-511. doi: 10.1007/s00223-020-00786-0
[10]	Anna K, Karolina S, Karolina I, et al. FGF23: A review of its role in mineral metabolism and renal and cardiovascular disease[J]. Dis Markers, 2021, 17(2021) : 8821292.
[11]	Sandro M, Giuseppe C, Antonio De P, et al. Bone, inflammation and the bone marrow niche in chronic kidney disease: What do we know?[J]. Nephrol Dial Transplant, 2018, 33(12): 2092-100. doi: 10.1093/ndt/gfy115 URL
[12]	Kazu HO, Yoshinori T, Yoshiko S, et al. Serum dickkopf-related protein 1 and sclerostin may predict the progression of chronic kidney disease in Japanese patients[J]. Nephrol Dial Transplant, 2019, 34(8): 1426-1427. doi: 10.1093/ndt/gfz078 URL
[13]	Neto R, Pereira L, Magalhães J, et al. Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4[J]. Clin Kidney J, 2021, 14(11): 2401-2408. doi: 10.1093/ckj/sfab081 pmid: 34754436
[14]	Saeedeh HH, Mohammad T, Sadegh J. Soy isoflavones and bone health: Focus on the RANKL/RANK/OPG pathway[J]. Biomed Resear Int, 2022: 8862278.
[15]	Evenepoel P, Opdebeeck B, David K, et al. Bone-vascular axis in chronic kidney disease[J]. Adv Chronic Kidney Dis, 2019, 26(6): 472-483. doi: 10.1053/j.ackd.2019.09.006 URL
[16]	Laetitia M, Zineb B, Anteneh A, et al. The roles of RANK/RANKL/OPG in cardiac, skeletal, and smooth muscles in health and disease[J]. Front Cell Dev Biol, 2022, 26(10): 903657.
[17]	Rizzoli R. Vitamin D supplementation: upper limit for safety revisited?[J]. Aging clinical and experimental research, 2021, 33(1): 19-24. doi: 10.1007/s40520-020-01678-x
[18]	Kosaku N, Aiji Y, Ken T. Management of osteoporosis in chronic kidney disease[J]. Intern Med, 2017, 56(24): 3271-3276. doi: 10.2169/internalmedicine.8618-16 URL
[19]	Geeta H, Grahame JE, Martine CS, et al. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease[J]. Endocrine, 2021, 73(3): 509-529. doi: 10.1007/s12020-021-02735-9 pmid: 33974225
[20]	Pieter E, John C, Serge F, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D[J]. Nephrol Dial Transplant, 2021, 36(1): 42-59. doi: 10.1093/ndt/gfaa192 URL
[21]	国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 52-57.
[22]	Fellype CB, Sérgio GEB. Treatment of osteoporosis in chronic kidney disease[J]. J'Brase Nefrol, 2021, 43(< W>4 Suppl 1): 654-659.
[23]	Daniel C, Katharina K, Till B, et al. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study[J]. Kidney Blood Pres Res, 2010, 33(3): 221-226.
[24]	Kao CC, Wu PC, Chuang MT, et al. Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease[J]. Postgrad Med J, 2023, 99(1170):340-349. doi: 10.1136/postgradmedj-2021-140341 URL
[25]	Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: A review[J]. Am J Kidney Dis, 2022, 79(3):427-436. doi: 10.1053/j.ajkd.2021.06.031 URL
[26]	Mohammad T, Mohammed HM, Negin A, et al. RANKL/RANK/OPG pathway: A mechanism involved in exercise-induced bone remodeling[J]. BioMed Res Int, 2020, 19(2020): 6910312.
[27]	Khairallah P, Nickolas TL. Updates in CKD-associated osteoporosis[J]. Curr Osteoporos Rep, 2018, 16(6):712-723. doi: 10.1007/s11914-018-0491-3 pmid: 30353319
[28]	McKee H, Ioannidis G, Lau A, et al. Correction to: comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients[J]. Osteoporos Int, 2020, 31(5):981. doi: 10.1007/s00198-020-05381-5 pmid: 32189031
[29]	Chen CL, Chen NC, Wu FZ, et al. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study[J]. Osteoporos Int, 2020, 31(8):1507-1516. doi: 10.1007/s00198-020-05391-3 pmid: 32246167
[30]	Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension[J]. J Bone Miner Res, 2018, 33(2):190-198. doi: 10.1002/jbmr.3337 pmid: 29105841
[31]	Broadwell A, Chines A, Ebeling PR, et al. Denosumab safety and efficacy among participants in the freedom extension study with mild to moderate chronic kidney disease[J]. Clin Endocrinol Metab, 2021, 106(2):397-409. doi: 10.1210/clinem/dgaa851 URL
[32]	李梅, 章振林, 夏维波. 骨质疏松症药物治疗的必由之路:长程序贯治疗[J]. 中华骨质疏松和骨矿盐疾病杂志, 2021, 14(5): 441-446.
[33]	Chandra A, Rajawat J. Skeletal aging and osteoporosis: Mechanisms and therapeutics[J]. Int J Mol Sci, 2021, 22(7):3553. doi: 10.3390/ijms22073553 URL
[34]	Hara T, Hijikata Y, Matsubara Y, et al. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D[J]. Cochrane Database Syst Rev, 2021, 7(7):CD013424.

慢性肾脏病合并骨质疏松症治疗的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张娜娜, 崔轶霞, 邹琳. 类风湿关节炎患者骨密度与维生素D相关性研究进展[J]. 临床荟萃, 2024, 39(1): 92-96.
[2]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[3]	蒋炜, 田敏涛, 李学渊. 血清营养指标与老年骨质疏松症关系的研究进展[J]. 临床荟萃, 2023, 38(7): 668-672.
[4]	宗廷妮, 戴光荣, 赵晓宇, 李瑞风, 柴聪敏. 代谢相关脂肪性肝病靶向药物治疗进展[J]. 临床荟萃, 2023, 38(4): 373-376.
[5]	罗方林, 官素英, 吴国祥. 沙库巴曲缬沙坦钠联合新活素治疗急性左心衰竭的疗效[J]. 临床荟萃, 2021, 36(9): 782-785.
[6]	周耀, 魏博涛, 沈阳. 人腺病毒感染的药物治疗新进展[J]. 临床荟萃, 2021, 36(7): 669-672.
[7]	卢昊阳, 卢家忠, 韩明锋, 吕新才, 张标, 戎成振, 贾蕾蕾, 潘强强, 马蕾蕾, 赵韧. 新型冠状病毒肺炎合并心血管疾病的临床治疗观察[J]. 临床荟萃, 2021, 36(3): 203-207.
[8]	高兴连, 童宗武, 杨崇猛, 赵艳红, 卢永新, 丁蓉. 序贯化疗系统性免疫球蛋白轻链型淀粉样变性肾病1例[J]. 临床荟萃, 2021, 36(3): 266-269.
[9]	王艳军, 崔炜. 降压治疗中低血压的成因及处理[J]. 临床荟萃, 2021, 36(3): 270-276.
[10]	张佳红，周淑红，周静，王慧娟. 沙利度胺治疗结缔组织病相关肺间质疾病的临床观察[J]. 临床荟萃, 2019, 34(7): 622-625.
[11]	贝丽叶1, 2，史玉叶1, 2，王春玲1, 2. 来那度胺在复发难治性非霍奇金B细胞淋巴瘤治疗中的应用[J]. 临床荟萃, 2019, 34(6): 508-513.
[12]	林晓红1，2，李鸿茹2, 3，陈愉生2，3，林丹2，陈诗杰2，谢剑峰4. 三甲医院重症社区获得性肺炎治疗现状分析[J]. 临床荟萃, 2019, 34(2): 132-135.
[13]	刘雪梅，张昌红，刘晓静. 服阿奇霉素联合噻托溴铵粉吸入剂治疗支气管扩张伴阻塞性通气功能障碍患者的疗效观察[J]. 临床荟萃, 2018, 33(9): 805-807.
[14]	Ted Wu1，刘珊2，许樟荣3. 糖尿病药物治疗新进展[J]. 临床荟萃, 2017, 32(8): 654-657.
[15]	韩菲，张晓岚. 胃食管反流病的药物治疗[J]. 临床荟萃, 2017, 32(1): 17-21.